Pharmaceutical - Pharmaceutical, Pharmacyclics

Filter

Popular Filters

Non-Hodgkin lymphoma market to grow to $9.2 billion

Non-Hodgkin lymphoma market to grow to $9.2 billion

29-10-2014

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

Celgene Corp.EuropeGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonMabTheraOncologyPharmaceuticalPharmacyclicsResearchRevlimidRocheUSAVelcadeZydelig

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

US FDA grants approval for Imbruvica for chronic lymphocytic leukemia

US FDA grants approval for Imbruvica for chronic lymphocytic leukemia

29-07-2014

The US Food and Drug Administration has granted USA-based Pharmacyclics approval for Imbruvica (ibrutinib)…

B-cell chronic lymphocytic leukemiaChronic lymphocytic leukemiaDanelle JamesImbruvicaJanssen BiotechOncologyPharmaceuticalPharmacyclicsRegulationUSA

US FDA approves sNDAs for Imbruvica and Azilect

US FDA approves sNDAs for Imbruvica and Azilect

09-06-2014

USA-based Pharmacyclics says that the US Food and Drug Administration has accepted for filing its supplemental…

AzilectImbruvicaNeurologicalOncologyPharmaceuticalPharmacyclicsRegulationTeva Pharmaceutical IndustriesUSA

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

FDA expands approval of Imbruvica to treat chronic lymphocytic leukemia

13-02-2014

The US Food and Drug Administration yesterday expanded the approved use of US health care giant Johnson…

ImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics signs deal with Lonza to support manufacturing of Imbruvica

Pharmacyclics signs deal with Lonza to support manufacturing of Imbruvica

13-01-2014

USA-based Pharmacyclics has signed a deal with Swiss chemical supplier Lonza for the commercial and clinical…

ImbruvicaLonzaOncologyPharmaceuticalPharmacyclicsProductionUSA

Janssen and Pharmacyclics’ Imbruvica meets key endpoints early in Phase III leukemia trial

Janssen and Pharmacyclics’ Imbruvica meets key endpoints early in Phase III leukemia trial

08-01-2014

USA-based Pharmacyclics and co-developer Janssen Biotech have announced that an Independent Data Monitoring…

ImbruvicaJanssen BiotechOncologyPharmaceuticalPharmacyclicsResearchUSA

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

US FDA approves Johnson & Johnson’s Imbruvica for rare blood cancer

14-11-2013

The US Food and Drug Administration yesterday approved US health care giant Johnson & Johnson’s Imbruvica…

ibrutinibImbruvicaJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclics

FDA acceptance of ibrutinib NDA triggers milestone for Pharmacyclics

30-08-2013

California, USA-based Pharmacyclics (Nasdaq: PCYC) said yesterday (August 29, 2013) that the US Food…

BiotechnologyibrutinibJanssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Study of mechanism of ibrutinib action in mantle cell lymphoma

22-08-2013

A study that investigated the mechanism of ibrutinib's anti-tumor effect in patients with mantle cell…

ibrutinibJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Janssen submits NDA for "breakthrough" leukemia and lymphoma drug ibrutinib

11-07-2013

Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson (NYSE: JNJ), has submitted…

ibrutinibJanssen PharmaceuticaJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulation

Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

16-06-2013

Among presentations over the weekend at the Congress of European Hematology Association (EHA) being held…

AbbVieBristol-Myers SquibbelotuzumabibrutinibIncyteJakaviJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data

09-04-2013

Pharmacyclics (Nasdaq: PCYC) saw its shares gain 4.5% to $78.96 in early trading Monday, after it revealed…

ibrutinibJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib

14-02-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib

11-12-2012

During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

Pharmacyclics gets second $50 million milestone from Janssen

21-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics gets $50 milestone from J&J on ibrutinib progress

03-08-2012

California, USA-based Pharmacyclics (Nasdaq: PCYC) says it that enrolment of the fifth patient in the…

FinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

19-02-2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC)…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalPharmacyclics

Back to top